ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,718.57
      0.28%
      US Tech 100
      19,312.80
      0.08%
      Dow Jones
      42,124.65
      0.15%
      Brent Oil
      73.76
      0.03%
      Bitcoin
      63,099.46
      -0.36%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Coherus BioSciences Inc (CHRS) Quote

      Coherus BioSciences Inc

      Coherus BioSciences Inc (CHRS)

      NASDAQ
      1.04
      0.02
      (1.96%)
      Closed September 23 4:00PM
      Delayed by 15 minutes
      1.0395
      -0.0005
      (-0.05%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      1.0395
      Bid
      1.03
      Ask
      1.04
      Volume
      3,890,002
      0.9735 Day's Range 1.04
      1.0051 52 Week Range 4.36
      Market Cap
      119.759M
      Previous Close
      1.02
      Open
      1.02
      Last Trade
      2000
      @
      1.0395
      (formt)
      Last Trade Time
      Financial Volume
      $ 3,938,129
      VWAP
      1.0124
      Average Volume (3m)
      1,912,052
      Shares Outstanding
      115,208,583
      Dividend Yield
      -
      PE Ratio
      -0.50
      Earnings Per Share (EPS)
      -2.06
      Revenue
      257.24M
      Net Profit
      -237.89M

      About Coherus BioSciences Inc

      Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.coherus.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Coherus BioSciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CHRS. The last closing price for Coherus BioSciences was $1.02. Over the last year, Coherus BioSciences shares have traded in a share price range of $ 1.0051 to $ 4.36.

      Coherus BioSciences currently has 115,208,583 shares outstanding. The market capitalization of Coherus BioSciences is $117.51 million. Coherus BioSciences has a price to earnings ratio (PE ratio) of -0.50.

      Ask ADVFN Intelligence (AI)

      CHRS Latest News

      More News

      Form 8-K - Current report

      September 13 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      August 09 2024
      Edgar (US Regulatory)

      Form S-8 - Securities to be offered to employees in employee benefit plans

      August 08 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 08 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 08 2024
      Edgar (US Regulatory)

      Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

      – Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI – – Bryan McMichael...

      August 08 2024
      GlobeNewswire Inc.

      Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

      REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after...

      August 01 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      July 24 2024
      Edgar (US Regulatory)

      Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

      REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend...

      June 27 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      June 05 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.2805-21.251.321.321.005144073081.05410992CS
      4-0.3705-26.27659574471.411.491.005119229611.16937182CS
      12-0.7005-40.25862068971.741.9051.005119120521.35961677CS
      26-1.2905-55.38626609442.332.611.005117851111.70930326CS
      52-3.3205-76.15825688074.364.361.005134421512.36804691CS
      156-15.9605-93.88529411761719.321.005121145644.77062677CS
      260-20.7405-95.227272727321.7823.911.005117024408.02134126CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      KAVLKaival Brands Innovations Group Inc
      $ 1.33
      (129.71%)
      		182.46M
      LASELaser Photonics Corporation
      $ 18.8671
      (81.24%)
      		13.54M
      TGLTreasure Global Inc
      $ 1.18
      (73.45%)
      		139.95M
      NVVENuvve Holding Corporation
      $ 6.68
      (70.41%)
      		31.34M
      UXINUxin Ltd
      $ 2.42
      (52.68%)
      		18.24M
      ELABElevai Labs Inc
      $ 0.10545
      (-62.34%)
      		23.66M
      ADTXAditxt Inc
      $ 0.262
      (-31.52%)
      		3.17M
      FRGTFreight Technologies Inc
      $ 0.081
      (-28.82%)
      		26.35M
      ANEBAnebulo Pharmaceuticals Inc
      $ 2.23
      (-27.60%)
      		113.78k
      STSSSharps Technology Inc
      $ 0.1722
      (-27.06%)
      		2.27M
      XPONExpion360 Inc
      $ 0.1144
      (34.91%)
      		432.14M
      NVDANVIDIA Corporation
      $ 116.26
      (0.22%)
      		206.23M
      INTCIntel Corporation
      $ 22.56
      (3.30%)
      		184.43M
      KAVLKaival Brands Innovations Group Inc
      $ 1.33
      (129.71%)
      		182.45M
      TGLTreasure Global Inc
      $ 1.18
      (73.45%)
      		139.93M

      CHRS Discussion

      View Posts
      Monksdream Monksdream 1 week ago
      CHRS new 52 week low
      👍️0
      Monksdream Monksdream 2 months ago
      CHRS under $2
      👍️0
      Monksdream Monksdream 2 months ago
      CHRS under $2
      👍️0
      glenn1919 glenn1919 2 months ago
      CHRS...................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 5 months ago
      CHRS under $3
      👍️0
      frans frans 7 months ago
      short interest about 28.000.000 milj.up 7% today
      👍️0
      Mile High Marauder Mile High Marauder 7 months ago
      Here is short interest link

      https://www.nasdaq.com/market-activity/stocks/chrs/short-interest
      👍️0
      frans frans 7 months ago
      you know how many shorts we have here to cover ????
      my last buy was 2.08
      👍️0
      Mile High Marauder Mile High Marauder 7 months ago
      I think selling these non core assets, with the probability of selling more has greatly diminished the need to raise money and has put some pressure on the shorts to cover some of this massive short. IMO
      👍️ 1
      frans frans 8 months ago
      Coherus’ oncology assets include the UDENYCA® (pegfilgrastim-cbqv) franchise, with three FDA-approved presentations; LOQTORZI™ (toripalimab-tpzi), an FDA-approved, next-generation PD-1 inhibitor; and an immuno-oncology pipeline of next-generation tumor microenvironment oncology drug candidates.

      Closing is anticipated in from jan 22
      👍️0
      Mile High Marauder Mile High Marauder 8 months ago
      What fda news are u looking for?
      👍️0
      frans frans 8 months ago
      up 14 % FDA news is coming
      👍️0
      frans frans 8 months ago
      MM's we see an small cover now ? or company sell more ??,
      👍️0
      Mile High Marauder Mile High Marauder 8 months ago
      27million share short. I wonder what the true valuation of the company is? I sure hope the shorts have to cover some day. I can’t say I’ve Seen a short this large on a listed stock. Implosion or explosion ,I guess only time will tell.
      👍️0
      moonurneighbor moonurneighbor 8 months ago
      I think they are preparing for a sale
      👍️0
      Awl416 Awl416 8 months ago
      Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
      👍️0
      frans frans 8 months ago
      up from here now for the 1e FDA news
      👍️0
      frans frans 8 months ago
      company dump big big here
      👍️0
      frans frans 8 months ago
      have we an new company dump now ???????
      👍️0
      frans frans 9 months ago
      now up from here and wait on FDA news (should be good)
      👍️0
      glenn1919 glenn1919 9 months ago
      CHRS...........................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
      👍️0
      tbonaces80 tbonaces80 9 months ago
      Cup and handle formed
      👍️0
      tbonaces80 tbonaces80 9 months ago
      We will test HOD. HH and HL’s
      👍️0
      Mile High Marauder Mile High Marauder 9 months ago
      I find it hard to believe they’re going to dilute this company by 40% at this point Or at this price but you never know.
      👍️0
      Sierra20 Sierra20 9 months ago
      Offering?
      👍️0
      eneels01 eneels01 9 months ago
      Company needs to issue 40M shares at $2/sh. This would raise $80M, which would be enough to get through mid 2025…
      👍️0
      Mile High Marauder Mile High Marauder 10 months ago
      21 million share short!! What is going on!
      👍️0
      Monksdream Monksdream 10 months ago
      CHRS new 52 week low
      👍️0
      frans frans 10 months ago
      about end dec.23 finish tests 400 peoples - FDA commercialization about june 24 if no problems
      👍️0
      eneels01 eneels01 10 months ago
      Wow, instead of having a chance to go to $9, this stock has more of a chance to hit $1 by 2024. Oh well, I will just keep averaging down and sell when it eventually hits $5 again. Unfortunately that might not take place until 2025 or even 2026…
      👍️0
      frans frans 10 months ago
      I selled and come back begin jan 24 after finish test 400 peoples about end dec. 23
      👍️0
      Mile High Marauder Mile High Marauder 10 months ago
      Any idea who has this much stock to sell? I don’t see very many 5% holders.
      👍️0
      frans frans 11 months ago
      what is going on here ??
      👍️0
      TimeFades TimeFades 11 months ago
      Yup
      👍️0
      Monksdream Monksdream 11 months ago
      For now
      👍️0
      TimeFades TimeFades 11 months ago
      Looking strong
      👍️0
      Monksdream Monksdream 11 months ago
      Few and far between in the biomed sector this year
      👍️0
      frans frans 11 months ago
      slowly up from here
      👍️0
      Monksdream Monksdream 11 months ago
      CHRS morning rally
      👍️0
      TimeFades TimeFades 11 months ago
      Back in
      👍️0
      TimeFades TimeFades 11 months ago
      Sold out first thing at 4 watching
      👍️0
      TheFinalCD TheFinalCD 11 months ago
      WATCH 2:22
      👍️0
      Mile High Marauder Mile High Marauder 11 months ago
      Didn’t mean dog
      👍️0
      Mile High Marauder Mile High Marauder 11 months ago
      This dog has an 18 million shares short in it, somebody’s been betting big against it or think they know something we don’t
      👍️0
      TIMGZ TIMGZ 11 months ago
      INSTITUTIONS ARE BUYING UP ALL AND EVERY POTENTIALS******STILL, IT WILL EVENTUALLY DRIZZLE DOWN
      👍️0
      TheFinalCD TheFinalCD 11 months ago
      I bought the dip, but the float is practically owned by Institutions

      thats the problem I see here

      80% https://finviz.com/quote.ashx?t=CHRS&p=d
      👍️0
      TIMGZ TIMGZ 11 months ago
      CHRS****OPPORTUNITY TO BUY MORE OR STILL WAIT FOR DIRECTION??????????
      👍️0
      TheFinalCD TheFinalCD 11 months ago
      3.10 GOING WRONG WAY

      MAYBE THE NEWS ISNT AS BIG AS HOPED??
      👍️0
      TheFinalCD TheFinalCD 11 months ago
      LOQTORZI $CHRS

      What is nasopharyngeal carcinoma? Nasopharyngeal carcinoma (also known as NPC) is a rare tumor of the head and neck which originates in the nasopharynx. The nasopharynx is located at the very back of the nose near the Eustachian tubes (Figure).

      good part is

      LOQTORZI is the first and only FDA-approved treatment for NPC
      👍️0
      TimeFades TimeFades 11 months ago
      Moon?
      👍️0

      Your Recent History

      NASDAQ
      CHRS
      Coherus BioSciences
      Delayed Upgrade Clock